DEVELOP INTEGRATED DIAGNOSTIC BIOMARKERS OF ATHEROSCLEROSIS BASED ON EXPERIMENTAL STUDIES

Azizova, Dilzoda; Sobirova, Rikhsi; Islamova, Nodira; Rahmanova, Z; Ahmatova, K; Alimuhamedova, Mavjuda

dc.contributor.author	Azizova, Dilzoda
dc.contributor.author	Sobirova, Rikhsi
dc.contributor.author	Islamova, Nodira
dc.contributor.author	Rahmanova, Z
dc.contributor.author	Ahmatova, K
dc.contributor.author	Alimuhamedova, Mavjuda
dc.date.accessioned	2022-02-15T17:25:33Z
dc.date.available	2022-02-15T17:25:33Z
dc.date.issued	2022
dc.identifier.issn	2455-3301
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/1913
dc.description.abstract	The study examined the effect of Biomaysa on the content of apoprotein in and total cholesterol, lipoprotein cholesterol and Lp FLA 2 in the dynamics of experimental hypercholesterolemia. Apoprotein B. of combined administration Biomaysa and ultroksa installed significant difference in the reduction of total cholesterol levels in ApoB 2.2 and 1.5, indicating good cholesterol reducing the effectiveness of the combination of these drugs by activating LDL receptor capture.	en_US
dc.language.iso	en	en_US
dc.publisher	World Journal of Pharma and medical research	en_US
dc.subject	experimental hypercholesterolemia, blood, atherosclerosis, lipoproteins, cholesterol, apoprotein B, Lp FLA 2.	en_US
dc.title	DEVELOP INTEGRATED DIAGNOSTIC BIOMARKERS OF ATHEROSCLEROSIS BASED ON EXPERIMENTAL STUDIES	en_US
dc.type	Article	en_US